Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Ion channel modulator (Kv7 activator)

Azetukalner

An investigational treatment for Focal Epilepsy.

Phase 3by Xenon Pharmaceuticals
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Azetukalner wherever you encounter it, plus the key facts at a glance.

Generic name
Azetukalner
Development code
XEN1101
Drug class
Ion channel modulator (Kv7 activator)
Manufacturer
Xenon Pharmaceuticals
How it's taken
Taken by mouth once daily, as add-on therapy on top of a patient's existing seizure medicines.

An investigational once-daily Kv7 potassium-channel opener from Xenon Pharmaceuticals, the same mechanism class as opakalim.

It is the most advanced Kv7 program in epilepsy, with a positive Phase 3 focal-seizure study reported in 2026 and an FDA application submitted in September 2026.

Follow Azetukalner by email

We'll email you when the FDA acts on Azetukalner and when new trials for Focal Epilepsy open. Unsubscribe anytime.

You'll get, for Focal Epilepsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Azetukalner fits

An investigational once-daily Kv7 opener positioned for patients not adequately controlled on existing mechanisms, the same target class as opakalim, and the most advanced Kv7 program, with positive Phase 3 focal-seizure data in 2026.

How Azetukalner works

Like opakalim, azetukalner turns on Kv7 potassium channels, the natural 'off switch' on nerve cells. When these channels open, potassium flows out and the cell settles down, making it harder to fire the runaway bursts that start a focal seizure. Azetukalner targets the Kv7.2 and Kv7.3 channels most relevant to seizure control.

This is the same validated target that the withdrawn drug ezogabine (Potiga) proved could work in epilepsy. Azetukalner and opakalim are the two leading efforts to deliver that benefit with a cleaner, more selective molecule that avoids ezogabine's tolerability problems[2].

Clinical trial results

In the Phase 3 X-TOLE2 study (NCT05614063), azetukalner significantly reduced monthly focal-seizure frequency in adults with highly treatment-resistant epilepsy (a median of 5 prior seizure medicines). Topline results reported in March 2026 showed a median reduction of about 53% at the 25mg dose versus roughly 10% for placebo, a placebo-adjusted improvement of about 43%[1].

A second focal-seizure Phase 3 study, X-TOLE3 (NCT05716100), is recruiting, along with the Phase 3 X-ACKT study (NCT05667142) in primary generalized tonic-clonic seizures. Xenon announced on September 17, 2026 that it had submitted a New Drug Application to the FDA for focal seizures, based on the X-TOLE and X-TOLE2 studies[6][5][3].

Main registered trial: NCT05614063 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

In the Phase 3 X-TOLE2 study, dizziness was reported by 20.5% of people across both azetukalner doses, compared with 3.2% on placebo. Side effects led 14.5% of people on 25mg, 4.8% on 15mg and 3.2% on placebo to stop treatment[1].

On September 17, 2026, Xenon paused new enrollment in its depression and bipolar depression studies of azetukalner after reviewing neuropsychiatric side effects, in consultation with the studies' Data Safety Monitoring Board. Xenon said the pause does not affect its epilepsy studies[6].

Because azetukalner is still investigational, its complete safety profile, including any rare risks, will be defined by the full Phase 3 data and, ultimately, the FDA label if it is approved.

These are the safety findings reported so far, often by the company running the trials, not a complete safety picture. A study team or doctor can explain what to expect.

Taking Azetukalner

Taken by mouth once daily, as add-on therapy on top of a patient's existing seizure medicines. The pivotal Phase 3 studies tested 15mg and 25mg once-daily doses. Outside of a clinical trial, azetukalner is not yet available[4].

Development history

Azetukalner (development code XEN1101) was developed by Xenon Pharmaceuticals, a company focused on ion-channel drugs. After a positive Phase 2b study (X-TOLE) established the drug's promise, Xenon advanced it into a broad Phase 3 program across multiple seizure types. The positive X-TOLE2 readout in 2026 positioned azetukalner as the most advanced Kv7 activator in epilepsy and a direct benchmark for opakalim[1][2].

Ask anything about Azetukalner
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Focal Epilepsy trials

Other Focal Epilepsy treatments

Azetukalner and opakalim (BHV-7000) are the two leading Kv7 potassium-channel openers in late-stage epilepsy development, both aiming to revive a mechanism validated by ezogabine (Potiga) but without its retinal and skin-pigmentation liabilities. Azetukalner is further along, with positive Phase 3 focal-seizure data reported in early 2026 and an FDA application submitted on September 17, 2026.

Opakalim's first pivotal readout, RISE 3, is expected in the second half of 2026, and its program has been on a partial FDA clinical hold since September 4, 2026.

Common questions about Azetukalner

▸What is Azetukalner?

An investigational once-daily Kv7 potassium-channel opener from Xenon Pharmaceuticals, the same mechanism class as opakalim. It is the most advanced Kv7 program in epilepsy, with a positive Phase 3 focal-seizure study reported in 2026 and an FDA application submitted in September 2026.

▸How does Azetukalner work?

Like opakalim, azetukalner turns on Kv7 potassium channels, the natural 'off switch' on nerve cells. When these channels open, potassium flows out and the cell settles down, making it harder to fire the runaway bursts that start a focal seizure. Azetukalner targets the Kv7.2 and Kv7.3 channels most relevant to seizure control.

This is the same validated target that the withdrawn drug ezogabine (Potiga) proved could work in epilepsy. Azetukalner and opakalim are the two leading efforts to deliver that benefit with a cleaner, more selective molecule that avoids ezogabine's tolerability problems[2].

▸What are the side effects of Azetukalner?

In the Phase 3 X-TOLE2 study, dizziness was reported by 20.5% of people across both azetukalner doses, compared with 3.2% on placebo. Side effects led 14.5% of people on 25mg, 4.8% on 15mg and 3.2% on placebo to stop treatment[1].

On September 17, 2026, Xenon paused new enrollment in its depression and bipolar depression studies of azetukalner after reviewing neuropsychiatric side effects, in consultation with the studies' Data Safety Monitoring Board. Xenon said the pause does not affect its epilepsy studies[6].

Because azetukalner is still investigational, its complete safety profile, including any rare risks, will be defined by the full Phase 3 data and, ultimately, the FDA label if it is approved.

▸How is Azetukalner taken?

Taken by mouth once daily, as add-on therapy on top of a patient's existing seizure medicines. The pivotal Phase 3 studies tested 15mg and 25mg once-daily doses. Outside of a clinical trial, azetukalner is not yet available[4].

▸Is Azetukalner FDA approved?

Azetukalner is currently in phase 3 clinical trials for Focal Epilepsy. It has not yet received FDA approval.

▸What is azetukalner used for?

Azetukalner (XEN1101) is an investigational once-daily Kv7 potassium-channel opener from Xenon Pharmaceuticals being studied as add-on treatment for focal seizures in adults with treatment-resistant epilepsy. It is also in a Phase 3 study, X-ACKT, for primary generalized tonic-clonic seizures. [1][3]

▸Is azetukalner FDA approved?

No, azetukalner is not FDA-approved. It is a Phase 3 drug, and Xenon announced on September 17, 2026 that it had submitted a New Drug Application to the FDA for focal seizures. Outside of a clinical trial, azetukalner is not yet available. [6][4]

▸What did the azetukalner X-TOLE2 trial show?

In the Phase 3 X-TOLE2 study (NCT05614063), azetukalner significantly reduced monthly focal-seizure frequency in adults who had tried a median of 5 prior seizure medicines. Topline results reported in March 2026 showed a median seizure reduction of about 53% at the 25mg dose versus roughly 10% for placebo, a placebo-adjusted improvement of about 43%. [1]

▸What are the side effects of azetukalner?

In the Phase 3 X-TOLE2 study, dizziness was reported by 20.5% of people across both azetukalner doses, compared with 3.2% on placebo, and side effects led 14.5% of people on the 25mg dose to stop, compared with 3.2% on placebo. In September 2026 Xenon paused new enrollment in its depression studies after reviewing neuropsychiatric side effects, and said its epilepsy studies are not affected. The complete safety profile will be defined by the full Phase 3 data and any eventual FDA label. [1][6]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Xenon Pharmaceuticals (GlobeNewswire) · 2026-03-09. Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS). https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/xenon-announces-positive-topline-data-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-fos.html
  2. NeurologyLive · 2026-03-13. Phase 3 X-TOLE2 Data Support NDA Submission for Azetukalner in Focal Onset Seizures. https://www.neurologylive.com/view/phase-3-x-tole2-data-support-nda-submission-azetukalner-focal-onset-seizures
  3. U.S. National Library of Medicine, ClinicalTrials.gov. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT). https://clinicaltrials.gov/study/NCT05667142
  4. U.S. National Library of Medicine, ClinicalTrials.gov. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2). https://clinicaltrials.gov/study/NCT05614063
  5. U.S. National Library of Medicine, ClinicalTrials.gov. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3). https://clinicaltrials.gov/study/NCT05716100
  6. Xenon Pharmaceuticals · 2026-09-17. Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program. https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-azetukalner-nda-submission-fda-focal-seizures

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Azetukalner by email

We'll email you when the FDA acts on Azetukalner and when new trials for Focal Epilepsy open. Unsubscribe anytime.

You'll get, for Focal Epilepsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site